NovaDigm Therapeutics

Latest Headlines

Latest Headlines

Little NovaDigm races Pfizer, Glaxo in drive to develop MRSA vaccine

The lethal spread of MRSA in hospitals and other public places has been driving a number of programs aimed at finding a new vaccine capable of preventing tens of thousands of deaths each year.

First 'cross-kingdom' vax effective in PhI

NovaDigm Therapeutics is developing a vaccine that could work against both bacteria and fungi, and could even combat resistant bacteria such as MRSA. The company presented Phase I results at the 15th Annual Conference on Vaccine Research.